Affimed N.V. AFMD
Set alert
At close · Mar 12
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.1815
- Prev close
- 0.1815
- Mkt cap
- 20.33M
- Vol
- 22.06M
- Avg vol
- 256.67K
- EPS
- -4.72
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1815
- High
- 0.1815
- Forward P/E
- -0.48
- Beta
- 2.10
- Short ratio
- 12.46
- Inst. own
- 36.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 28, 2024
- 50-d avg
- 2.89
- 200-d avg
- 4.40
- 1y target
- 18.70
News
1 year ago benzinga.com
Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
US Stocks Edge Higher; Consumer Sentiment Falls In May
US Stocks Edge Higher; Consumer Sentiment Falls In May
1 year ago globenewswire.com
Affimed Announces Receipt of Nasdaq Delisting Notice
MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
1 year ago benzinga.com
This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
1 year ago globenewswire.com
Affimed Announces Filing for the Opening of Insolvency Proceedings
MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today…
1 year ago https://www.marketscreener.com
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to…
1 year ago globenewswire.com
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
1 year ago globenewswire.com
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their…
1 year ago globenewswire.com
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
1 year ago globenewswire.com
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
1 year ago globenewswire.com
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their…
1 year ago globenewswire.com
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
1 year ago globenewswire.com
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
1 year ago globenewswire.com
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
MANNHEIM, Germany, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
1 year ago zacks.com
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Affimed's acimtamig in combination with AlloNK for treating Hodgkin lymphoma. Shares fall.
1 year ago globenewswire.com
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory…
1 year ago seekingalpha.com
Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript
Affimed N.V. (NASDAQ:AFMD ) Q3 2024 Earnings Call Transcript November 14, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations & Director of Investor Relations Shawn…
1 year ago globenewswire.com
Affimed Reports Third Quarter 2024 Financial Results & Business Update
MANNHEIM, Germany, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
-
1 year ago benzinga.com
Earnings Scheduled For November 14, 2024
Earnings Scheduled For November 14, 2024
1 year ago globenewswire.com
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,…
2 years ago globenewswire.com
Affimed to Present at the Cantor Global Healthcare Conference 2024
MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their…
2 years ago seekingalpha.com
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
Affimed N.V. (NASDAQ:AFMD ) Q2 2024 Earnings Conference Call September 5, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head, Investor Relations Shawn Leland - Chief Executive Officer Andreas…
2 years ago globenewswire.com
Affimed Reports Second Quarter 2024 Financial Results & Business Update
MANNHEIM, Germany, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate…
2 years ago seekingalpha.com
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
On 06/11/24, I published an article on Affimed focused on my belief the company's upcoming acimtamig update would be positive. It was, and Affimed's stock popped the next day. The stock has since…
-
2 years ago benzinga.com
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
-
3 years ago benzinga.com
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
-
3 years ago benzinga.com
Earnings Scheduled For May 23, 2023
Companies Reporting Before The Bell • ATRenew (NYSE:RERE) is estimated to report quarterly earnings at $0.03 per share on revenue of $405.22 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 469 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 175 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 497 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 79 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 135 companies reached new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday saw 196 companies set new 52-week lows.
-
3 years ago benzinga.com
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
-
3 years ago benzinga.com
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
-
3 years ago benzinga.com
Earnings Scheduled For November 15, 2022
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 838 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 404 stocks made new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 340 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 507 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 429 stocks made new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 951 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 422 stocks made new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows.